WO2000074727A3 - Radiopharmaceuticals and methods for imaging - Google Patents

Radiopharmaceuticals and methods for imaging Download PDF

Info

Publication number
WO2000074727A3
WO2000074727A3 PCT/CA2000/000661 CA0000661W WO0074727A3 WO 2000074727 A3 WO2000074727 A3 WO 2000074727A3 CA 0000661 W CA0000661 W CA 0000661W WO 0074727 A3 WO0074727 A3 WO 0074727A3
Authority
WO
WIPO (PCT)
Prior art keywords
node
surgical
procedure
probe
sentinel
Prior art date
Application number
PCT/CA2000/000661
Other languages
French (fr)
Other versions
WO2000074727A2 (en
Inventor
Dennis Eshima
John Thornback
Lorie Eshima
Scott D Simpson
Original Assignee
Resolution Pharm Inc
Dennis Eshima
John Thornback
Lorie Eshima
Scott D Simpson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolution Pharm Inc, Dennis Eshima, John Thornback, Lorie Eshima, Scott D Simpson filed Critical Resolution Pharm Inc
Priority to AU53784/00A priority Critical patent/AU5378400A/en
Publication of WO2000074727A2 publication Critical patent/WO2000074727A2/en
Publication of WO2000074727A3 publication Critical patent/WO2000074727A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols

Abstract

This invention discloses the concept of incorporating a radioactive agent and various dyes to enhance lymphatic drainage, sentinel and lymph nodes. The use of a gamma emitting radionuclide such as Tc-99m allows the localization of the lymph node(s) that allows the surgeon to initially plan the surgical procedure. On the day of the study the radiopharmaceutical may need to be injected imaged and with the skin marked externally to assist the surgeon in locating the node during surgery. In order to facilitate the surgical probe a gamma detecting surgical probe can assist in providing the relative location of the node. This procedure has been found to be useful, however it has often been difficult utilizing this procedure to find all of the nodes. This invention would incorporate the use of a radioactive probe with a dye, the addition of the dye into the particles would allow the physician to more rapidly indentify lymphatic channels, sentinel and other node(s) and allow them to be excised which would dramatically reduce the surgical time for the patient.
PCT/CA2000/000661 1999-06-04 2000-06-05 Radiopharmaceuticals and methods for imaging WO2000074727A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53784/00A AU5378400A (en) 1999-06-04 2000-06-05 Radiopharmaceuticals and methods for imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2273609 CA2273609A1 (en) 1999-06-04 1999-06-04 Radiopharmaceuticals and methods for imaging
CA2,273,609 1999-06-04

Publications (2)

Publication Number Publication Date
WO2000074727A2 WO2000074727A2 (en) 2000-12-14
WO2000074727A3 true WO2000074727A3 (en) 2001-08-23

Family

ID=4163595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000661 WO2000074727A2 (en) 1999-06-04 2000-06-05 Radiopharmaceuticals and methods for imaging

Country Status (3)

Country Link
AU (1) AU5378400A (en)
CA (1) CA2273609A1 (en)
WO (1) WO2000074727A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1419788A1 (en) * 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Contrast agent for the identification of lymph nodes
US7368099B2 (en) * 2003-02-27 2008-05-06 Kyushu University, National University Corporation MRI contrast agents
JP2004269439A (en) * 2003-03-10 2004-09-30 Motohiro Takeda Agent for detecting sentinel lymph node and method for detecting the same
US8597613B2 (en) * 2004-07-02 2013-12-03 Iso-Tex Diagnostics, Inc Radiolabeled lymphatic staining agents and methods for making
US7381400B2 (en) 2004-07-13 2008-06-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Injection of a radioactive dye for sentinel lymph node identification
US8956591B2 (en) 2008-05-15 2015-02-17 Osaka Prefectural Hospital Organization Method for detecting cancer using ICG fluorescence method
KR101228147B1 (en) 2010-08-13 2013-01-31 국립암센터 Sentinel lymph nodes marker comprising albumin labeled with a radioisotope, a near infrared fluorescent dye, and a visible dye
KR101552138B1 (en) * 2012-12-26 2015-09-10 국립암센터 Novel composition for labelling cancer lesion
KR102096469B1 (en) * 2014-08-13 2020-04-02 주식회사 셀비온 Complex of Mannosyl Serum Albumin, Method of Preparing the Same, Optical Imaging Probe and Kit Comprising the Same
KR101881692B1 (en) * 2017-03-17 2018-07-25 서울대학교산학협력단 Dye-conjugated mannosylated serum albumin complex and detecting composition for lymph node comprising thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667764A (en) * 1988-05-02 1997-09-16 Zynaxis, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US5866544A (en) * 1994-02-25 1999-02-02 Resolution Pharmaceuticals, Inc. Peptide-chelator conjugates
WO1999051628A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667764A (en) * 1988-05-02 1997-09-16 Zynaxis, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US5866544A (en) * 1994-02-25 1999-02-02 Resolution Pharmaceuticals, Inc. Peptide-chelator conjugates
WO1999051628A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AMOSCATO AA ET AL: "Receptor-mediated internalization of tuftsin by human polymorphonuclear leukocytes.", JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY, JUL 1983, VOL. 34, NO. 1, PAGE(S) 53-67, XP000990391 *
AMOSCATO AA ET AL: "Receptor-mediated internalization of tuftsin.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1983, VOL. 419, PAGE(S) 114-34, XP000990445 *
BLANKENBERG F G ET AL: "Imaging of apoptosis (programmed cell death) with 99mTc annexin V", JOURNAL OF NUCLEAR MEDICINE,US,SOCIETY OF NUCLEAR MEDICINE. NEW YORK, vol. 40, no. 1, January 1999 (1999-01-01), pages 184 - 191, XP002119666, ISSN: 0161-5505 *
BLANQUET P ET AL: "OCULAR SCINTIGRAPHY", JOURNAL OF NUCLEAR MEDICINE, vol. 15, no. 6, 1974, pages 478, XP000990359, ISSN: 0161-5505 *
DAVIS M A ET AL: "EVALUATION OF RADIO PHARMACEUTICALS SEQUESTERED BY ACUTELY DAMAGED MYO CARDIUM", JOURNAL OF NUCLEAR MEDICINE, vol. 17, no. 10, 1976, pages 911 - 917, XP000990358, ISSN: 0161-5505 *
ESHIMA DENNIS ET AL: "Technetium-99m-sulfur colloid for lymphoscintigraphy: Effects of preparation parameters.", JOURNAL OF NUCLEAR MEDICINE, vol. 37, no. 9, 1996, pages 1575 - 1578, XP002163259, ISSN: 0161-5505 *
HEINRICH R SCHELBERT E H ET AL: "IMAGING WITH INFARCT AVID AGENT", CRITICAL REVIEWS IN DIAGNOSTIC IMAGING, vol. 16, no. 3, 1981, pages 239 - 278, XP000990392, ISSN: 0147-6750 *
HORIUCHI K ET AL: "LIGANDIN BINDING PHTHALEIN COMPLEXONE COMPLEX OF TECHNETIUM FOR HEPATIC FUNCTION STUDIES", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, vol. 16, no. 3, 1990, pages 137 - 142, XP000990394, ISSN: 0340-6997 *
HUNG JOSEPH C ET AL: "Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy.", JOURNAL OF NUCLEAR MEDICINE, vol. 36, no. 10, 1995, pages 1895 - 1901, XP002163258, ISSN: 0161-5505 *
ORDA R ET AL: "POST SPLENECTOMY SPLENIC ACTIVITY", ANNALS OF SURGERY, vol. 194, no. 6, 1981, pages 771 - 774, XP000990400, ISSN: 0003-4932 *
PEERS S H ET AL: "Imaging a model of colitis with RP128, a Tc-99m-chelated tuftsin antagonist.", JOURNAL OF NUCLEAR MEDICINE, vol. 36, no. 5 SUPPL., 1995, 42nd Annual Meeting of the Society of Nuclear Medicine;Minneapolis, Minnesota, USA; June 12-15, 1995, pages 114P, XP002102963, ISSN: 0161-5505 *
SAJI H ET AL: "PHTHALEIN AND FLUORESCEIN DERIVATIVES WITH AN EFFECTIVE TECHNETIUM-99M LABELED STATE FOR A HEPATO BILIARY TRANSPORT TECHNETIUM-99M PHTHALEIN COMPLEXONE A NEW HEPATO BILIARY RADIO PHARMACEUTICAL", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 16, no. 1, 1979, pages 188 - 189, XP000990372, ISSN: 0362-4803 *
SECOND INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL CHEMISTRY, 3 July 1978 (1978-07-03) - 7 July 1978 (1978-07-07), St. Catherine's College, Oxford, GB *
SOM P ET AL: "Diagnosis of osteomyelitis and soft tissue infection using a Tc-99m labeled tuftsin-analog peptide.", JOURNAL OF NUCLEAR MEDICINE, vol. 38, no. 5 SUPPL., 1997, 44th Annual Meeting of the Society of Nuclear Medicine;San Antonio, Texas, USA; June 1-5, 1997, pages 132P, XP000990357, ISSN: 0161-5505 *
TERASHIMA M ET AL: "ADP-ribosylation of tuftsin suppresses its receptor-binding capacity and phagocytosis-stimulating activity to murine peritoneal macrophages.", FEBS LETTERS, JUL 21 1997, VOL. 412, NO. 1, PAGE(S) 227-32, XP000990355 *
TSUBOUCHI K: "EXPERIMENTAL STUDIES ON RENAL INFARCTION ESPECIALLY CHANGES OF LACTATE DEHYDROGENASE ISO ENZYME PATTERNS IN TISSUE EXTRACTS OF DOG KIDNEY", JOURNAL OF TOKYO MEDICAL COLLEGE, vol. 39, no. 2, 1981, pages 219 - 232, XP000990370, ISSN: 0040-8905 *
YAMADA RITSUKO ET AL: "A case of sternocostoclavicular hyperostosis with uveitis and secondary glaucoma.", JAPANESE JOURNAL OF CLINICAL OPHTHALMOLOGY, vol. 48, no. 3, 1994, pages 309 - 312, XP000990389, ISSN: 0370-5579 *

Also Published As

Publication number Publication date
AU5378400A (en) 2000-12-28
WO2000074727A2 (en) 2000-12-14
CA2273609A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
WO2000074727A3 (en) Radiopharmaceuticals and methods for imaging
Mountford et al. Comparison of technetium-99m-HM-PAO leukocytes with indium-111-oxine leukocytes for localizing intraabdominal sepsis
ES2177792T3 (en) COMPLEX POLYMERS IN CASCADA, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM.
DK0907379T3 (en) Bioactivated diagnostic imaging contrast agent
WO2008059489A3 (en) Radioimaging applications of and novel formulations of teboroxime
WO2002007600A3 (en) Test body and test body systems for nuclear medicine devices, production and use thereof
Haronian et al. Myocardial risk area defined by technetium-99m sestamibi imaging during percutaneous transluminal coronary angioplasty: comparison with coronary angiography
Louissaint et al. Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse
Babiera et al. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
Kelley et al. Tracer agents for the detection of sentinel lymph nodes in breast cancer: current concerns and directions for the future
Wong et al. F-18 FDG accumulation in an octreotide negative Merkel cell tumor
Haghighatafshar et al. Is brown adipose tissue visualization reliable on 99mTc-methoxyisobutylisonitrile diagnostic SPECT scintigraphy?
BRUNETTI et al. The value of SPECT imaging in the diagnosis of hepatic hemangioma
Ravizzini et al. Efficiency comparison between 99mTc-tetrofosmin and 99mTc-sestamibi myocardial perfusion studies
Liu et al. Novel 99mTc (III) Complexes [99mTcCl (CDO)(CDOH) 2B–R](CDOH2= Cyclohexanedione Dioxime) Useful as Radiotracers for Heart Imaging
ElBez et al. Bladder hernia mimicking bone metastasis: Case report with literature review
Losik et al. Chemotherapy-induced pericarditis on F-18 FDG positron emission tomography scan
Qin Recent advances of injectable radiopharmaceuticals for nuclear imaging and therapy: a new era in nuclear medicine
Barth et al. Beta-radiation exposure of medical personnel
Aigner et al. Parathyroid scintigraphy: first experiences with technetium (III)-99m-Q12
RU2000111591A (en) METHOD FOR DIAGNOSTIC OF FOCAL DISEASES OF THE SPLEEN
Weiss et al. First experiences with a new radiopharmaceutical for sentinel lymph node detection in malignant melanoma
Vorne et al. Thrombus imaging with 99mTc-HMPAO-labeled platelets and 111In-labeled monoclonal antifibrin antibodies
ATE401107T1 (en) INTRADUCTAL TREATMENT OF BREAST LESIONS COMPRISING THERAPEUTIC AND DIAGNOSTIC AGENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP